PEPG

PepGen Inc. (PEPG) 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: PepGen Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform.
Lead Asset: PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1).
Status: The company has no approved products and has not generated any revenue from product sales. It is an Emerging Growth Company (EGC) and a Smaller Reporting Company.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• R&D Expenses: Decreased by $5.4 million (7.1%) primarily due to the discontinuation of the Duchenne Muscular Dystrophy (DMD) program (PGN-EDO51) in May 2025, which reduced preclinical and manufacturing costs. This was partially offset by increased clinical trial costs for the lead DM1 program.
• Financing Activity: Significant capital raise in September 2025 via a public offering (2025 Offering), generating net proceeds of $107.6 million. This contrasts with the 2024 Offering which generated $76.4 million in net proceeds.
• Interest Income: Decreased by $3.1 million to $4.0 million, driven by lower cash balances prior to the September 2025 financing.
• Program Status: The company voluntarily discontinued development of PGN-EDO51 (DMD) in May 2025 following Phase 2 data readouts that did not meet dystrophin targets. Focus is now exclusively on PGN-EDODM1 (DM1).

Guidance, Outlook, and Risks

• Clinical Progress (PGN-EDODM1):
  • Phase 1 (FREEDOM): Completed. Reported robust, dose-dependent splicing correction (up to 53.7% at 15 mg/kg) with a favorable emerging safety profile. No meaningful functional improvements were seen after a single dose.
  • Phase 2 (FREEDOM2): Ongoing in Canada, U.K., South Korea, Australia, and New Zealand. The 5 mg/kg cohort has completed dosing; data expected Q1 2026. The 10 mg/kg cohort is currently dosing; data expected H2 2026.
  • Regulatory Hold: The FDA has placed a partial clinical hold on the FREEDOM2 study in the U.S. related to questions regarding previously submitted preclinical pharmacology and toxicology studies. The hold does not cite issues with the blinded Phase 1 clinical data. The company is submitting additional analyses to resolve this.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($148.5 million) are sufficient to fund planned operations into the second half of 2027.
• Key Risks:
  • Regulatory Uncertainty: Resolution of the FDA partial clinical hold is critical for U.S. enrollment in Phase 2.
  • Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to advance PGN-EDODM1 to Phase 3 and commercialization.
  • Development Risk: No functional improvements were observed in the single-dose Phase 1 study; efficacy in the multi-dose Phase 2 study is not guaranteed.
  • Competition: Several competitors are developing therapies for DM1, including antibody-linked siRNAs and other oligonucleotide approaches.

Investor Verification Checklist

• FDA Clinical Hold Status: Verify the current status of the partial clinical hold on the FREEDOM2 study and the timeline for potential U.S. site initiation.
• Phase 2 Data Readouts: Monitor the Q1 2026 data release for the 5 mg/kg cohort of FREEDOM2 to assess safety and splicing correction with repeat dosing.
• Cash Burn Rate: Confirm the run-rate of operating expenses and the sufficiency of the $148.5 million cash balance to reach the next major milestone without dilution.
• Functional Outcomes: Evaluate whether the robust splicing correction observed in Phase 1 translates to functional clinical benefits in the ongoing Phase 2 trial.
• Intellectual Property: Review the scope and expiration dates of the licensed patents from Oxford University Innovation and the Medical Research Council (MRC).